🌐Buy Enhertu Trastuzumab Deruxtecan Injection Online USA, UK, UAE Australia, Europe, United Kingdom, United States, Cambridge, London, Morocco, Indonesia, Chile, Peru, Ethiopia, Romania, China, Japan, Russia, Ukraine, Dubai, United Arab Emirates, South Korea, Africa, Thailand, Vietnam, Middle East, and Southeast Asian countries.

Introduction to Enhertu (Trastuzumab + Deruxtecan Injection)

Enhertu (trastuzumab deruxtecan) is an advanced targeted anti-cancer therapy used in the treatment of certain types of HER2-positive cancers, particularly breast cancer and gastric cancer. It belongs to a class of drugs known as antibody-drug conjugates (ADCs), combining the precision of targeted therapy with the potency of chemotherapy.

Enhertu works by specifically targeting HER2 (human epidermal growth factor receptor 2) proteins present on cancer cells, delivering a powerful cytotoxic agent directly into the tumor, thereby minimizing damage to healthy cells.

📞 Contact Details to Place Order

💬 WhatsApp: +91 9730316395
📞 Phone: +91 9730316395
📧 Email: info@globmedindia.com
🌐 Website: https://globmedindia.com

Composition and Content

Active Ingredient: Trastuzumab Deruxtecan
Drug Class: Antibody-Drug Conjugate (ADC)
Form: Lyophilized powder for injection
Strength: Commonly available as 100 mg vial

Key Components:

Trastuzumab: A monoclonal antibody targeting HER2 receptors
Deruxtecan: A topoisomerase I inhibitor (cytotoxic agent)
Linker: Connects antibody with chemotherapy drug, ensuring targeted delivery

How to Use

Administered as an intravenous (IV) infusion under medical supervision
Infusion is typically given over 30–90 minutes
Should only be used in a hospital or oncology clinic setting
Pre-medications may be given to prevent infusion-related reactions

Dosage

Standard recommended dose: 5.4 mg/kg body weight, once every 3 weeks (21-day cycle)
Dose adjustments may be required based on:
- Patient tolerance
- Side effects
- Liver function

Important: Always follow the oncologist’s prescription.

Uses

Enhertu is primarily used in the treatment of:

HER2-positive breast cancer (metastatic or unresectable)
HER2-low breast cancer (in specific cases)
HER2-positive gastric or gastroesophageal junction cancer

Treatments & Indications

Enhertu is indicated for patients who:

Have previously received anti-HER2-based therapies
Show progression after standard chemotherapy
Require targeted therapy with improved efficacy

It is widely used in second-line and later treatment settings.

Advantages

🎯 Targeted Therapy: Precisely attacks HER2-positive cancer cells
⚡ High Efficacy: Demonstrates strong tumor response rates
🔬 Innovative Mechanism: Combines biologic and chemotherapy action
📉 Reduced Systemic Toxicity: Less damage to healthy tissues compared to traditional chemo
⏳ Improved Survival Rates: Proven clinical benefits in advanced cancers

Storage Conditions

Store in a refrigerator (2°C to 8°C)
Do not freeze
Protect from light
Use immediately after reconstitution or as directed
Keep out of reach of children

Alternative Indian Brands

While Enhertu is a globally recognized brand, direct Indian generic equivalents are limited due to its advanced ADC technology. However, alternative HER2-targeted therapies include:

Herceptin (Trastuzumab)
Kadcyla (T-DM1)
Hertraz
Canmab

Note: These are not exact substitutes but may be used depending on clinical condition.